Tailored therapies based on tumor biology are needed to improve treatment response and ultimately patient survival. Current Opinion in Gastroenterology
A new trial shows that sorafenib, recently approved for liver cancer, is effective in Asian patients with poorer health status and more metastases. Medscape Medical News
Although the treatment response rate of pregnant women hospitalized with an inflammatory bowel disease relapse is high, the incidence of preterm birth and low birth weight infants is also high compared with inflammatory bowel disease patients who do not relapse during pregnancy. Reuters Health Information
A novel intravenous iron formulation, ferric carboxymaltose (Ferinject, Vifor International) appears to be particularly effective for the treatment of anemia in patients with inflammatory bowel disease (IBD), according to European researchers. Reuters Health Information
In this videoblog, Dr. Maurie Markman describes research that seeks to replace "one-treatment-fits-all" regimens for carcinoma of unknown primary with more tailored approaches based on molecular profiling. Medscape Hematology-Oncology
Introduction in early 2002 of the Model for End-Stage Liver Disease (MELD), a new liver donor organ allocation system allowing priority status to patients with limited-stage hepatocellular carcinoma (HCC), has resulted in a six-fold increase in the proportion of liver transplant recipients with HCC, research shows. Reuters Health Information
Proteins differentially expressed in a mouse model of pancreatic ductal adenocarcinoma are also present in early-stage disease in humans, scientists report in the June issue of PLoS Medicine. Reuters Health Information
There is a higher rate of sustained virologic response in patients with chronic hepatitis C virus (HCV) genotype 6 infection who are treated for 48 weeks with peginterferon or interferon and ribavirin, compared to those who receive only 24 weeks of treatment, according to California-based investigators. Reuters Health Information
Combination therapy with irbesartan and propranolol can produce greater sodium excretion than use of propranolol alone in certain patients with cirrhosis, according to German researchers. Reuters Health Information
